PerkinElmer (NYSE: PKI) and Edwards Lifesciences Corporation (NYSE:EW) are both mid-cap computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation.
This table compares PerkinElmer and Edwards Lifesciences Corporation’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Edwards Lifesciences Corporation||22.16%||27.17%||15.91%|
This is a breakdown of current ratings and target prices for PerkinElmer and Edwards Lifesciences Corporation, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Edwards Lifesciences Corporation||0||5||14||1||2.80|
PerkinElmer currently has a consensus target price of $66.91, indicating a potential downside of 3.70%. Edwards Lifesciences Corporation has a consensus target price of $120.05, indicating a potential upside of 6.53%. Given Edwards Lifesciences Corporation’s stronger consensus rating and higher possible upside, analysts clearly believe Edwards Lifesciences Corporation is more favorable than PerkinElmer.
Institutional and Insider Ownership
91.5% of PerkinElmer shares are owned by institutional investors. Comparatively, 82.1% of Edwards Lifesciences Corporation shares are owned by institutional investors. 2.2% of PerkinElmer shares are owned by insiders. Comparatively, 2.1% of Edwards Lifesciences Corporation shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares PerkinElmer and Edwards Lifesciences Corporation’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|PerkinElmer||$2.14 billion||3.58||$416.05 million||$3.31||20.99|
|Edwards Lifesciences Corporation||$3.23 billion||7.37||$1.05 billion||$3.30||34.15|
Edwards Lifesciences Corporation has higher revenue and earnings than PerkinElmer. PerkinElmer is trading at a lower price-to-earnings ratio than Edwards Lifesciences Corporation, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
PerkinElmer has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Comparatively, Edwards Lifesciences Corporation has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500.
PerkinElmer pays an annual dividend of $0.28 per share and has a dividend yield of 0.4%. Edwards Lifesciences Corporation does not pay a dividend. PerkinElmer pays out 8.5% of its earnings in the form of a dividend.
Edwards Lifesciences Corporation beats PerkinElmer on 12 of the 17 factors compared between the two stocks.
PerkinElmer Company Profile
PerkinElmer, Inc. is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets. It provides analytical instrumentation for the industrial market, which includes the chemical, electronics, energy, lubricant, petrochemical and polymer industries. Its products include AAnalyst, Altus, Aquamatic, Avio, AxION, Clarus, DairyGuard, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, Cell carrier and cell::explorer. The Diagnostics segment is focused on reproductive health, emerging market diagnostics and applied genomics. Its products include AutoDELFIA, BACS-on-Beads, Bioo Scientific, BoBs, Datalytix, Dexela, Dexela CMOS FPDs, Evolution, ViaCord, and Zephyr.
Edwards Lifesciences Corporation Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient’s cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.
Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.